(Daratumumab + hyaluronidase (human recombinant)) is under clinical development by Johnson & Johnson and currently in Phase II for Peripheral Neuropathy (Sensory Neuropathy). According to GlobalData, Phase II drugs for Peripheral Neuropathy (Sensory Neuropathy) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Daratumumab + hyaluronidase (human recombinant))’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Daratumumab + hyaluronidase (human recombinant)) overview
Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex, Darzquro, Dalinvi ) is a fixed dose combination act as antineoplastic agent developed based on halozyme's ENHANZE drug delivery technology. It is formulated as solution for subcutaneous route of administration. Darzalex Faspro is indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant, for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, for the treatment of adult patients with multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a proteasome inhibitor and an immunomodulatory agent, for the treatment of adult patients with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. Darzalex Faspro is indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Darzalex in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after the last therapy. It is indicated in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.
Daratumumab in combination with hyaluronidase is under development for the treatment of newly diagnosed and transplant-ineligible patients, MGUS associated peripheral neuropathy, refractory and relapsed multiple myeloma and T-cell acute lymphoblastic leukemia.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products and medical devices. The company conducts business through its operating companies. It provides pharmaceuticals for immune disorders, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; and medical devices for use in cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, healthcare professionals and hospitals. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US) and Latin America. J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of (Daratumumab + hyaluronidase (human recombinant))’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
